Published Online
on March 28, 2005

A more recent version of this article appeared on April 5, 2005

This Article Full Text (PDF) All Versions of this Article: 111/13/1685    most recent 01.CIR.0000160358.63804.C9v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steffel, J. Articles by Tanner, F. C. Search for Related Content PubMed PubMed Citation Articles by Steffel, J. Articles by Tanner, F. C. Related Collections Pathophysiology Cell signalling/signal transduction Coagulation Acute coronary syndromes Other Vascular biology

Submitted on September 30, 2004
Revised on December 9, 2004
Accepted on December 23, 2004

Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH₂ Kinase Phosphorylation

Jan Steffel MD, Matthias Hermann MD, Helen Greutert , Steffen Gay MD, Thomas F. Lüscher MD, Frank Ruschitzka MD, and Felix C. Tanner MD^*

From Cardiovascular Research (J.S., M.H., H.G., T.F.L., F.C.T.), Physiology Institute, University of Zürich; Cardiology, Cardiovascular Center (J.S., M.H., T.F.L., F.R., F.C.T.) and Center for Experimental Rheumatology (S.G.), University Hospital Zürich, Zürich, Switzerland.

^* To whom correspondence should be addressed. E-mail: felix.tanner{at}access.unizh.ch.

Background--Despite potential antiinflammatory properties, the use of selective cyclooxygenase-2 inhibitors (coxibs) in patients with cardiovascular diseases has been questioned because of a possibly increased thrombotic risk. Tissue factor (TF), a key protein for initiation of coagulation, has been implicated in the pathogenesis of atherosclerosis and thrombosis. Hence, we examined the effect of different coxibs on TF expression.

Methods and Results--Celecoxib (10^-5 mol/L), but not rofecoxib (10^-7 to 10^-5 mol/L) or the experimental coxib NS-398 (10^-7 to 10^-5 mol/L), decreased tumor necrosis factor--induced TF expression and activity in human aortic endothelial cells. Celecoxib (10^-5 mol/L) reduced activation of c-jun terminal NH₂ kinase (JNK), whereas it did not affect p38 mitogen-activated protein (MAP) kinase or p44/42 MAP kinase; in contrast, JNK activation was not affected by rofecoxib (10^-5 mol/L) or NS-398 (10^-5 mol/L). TF expression was reduced in a concentration-dependent manner by pretreatment with SP600125 (10^-7 to 10^-6 mol/L), a specific inhibitor of JNK, which confirms that JNK regulates tumor necrosis factor--induced TF expression.

Conclusions--Celecoxib reduced TF expression and activity in human aortic endothelial cells. Because neither rofecoxib nor the experimental coxib NS-398 affected TF expression, this effect occurs independently of COX-2 inhibition; it is rather mediated through inhibition of JNK phosphorylation. These data indicate a distinct heterogeneity within this class of drugs, which may be clinically relevant, especially for patients with atherosclerotic vascular diseases.

Key words: atherosclerosis • cardiovascular diseases • coagulation • endothelium • signal transduction

This article has been cited by other articles:

				A. Breitenstein, S.F. Stampfli, G.G. Camici, A. Akhmedov, H.R. Ha, F. Follath, A. Bogdanova, T.F. Luscher, and F.C. Tanner Amiodarone Inhibits Arterial Thrombus Formation and Tissue Factor Translation Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2231 - 2238. [Abstract] [Full Text] [PDF]

				B. E. Stahli, A. Breitenstein, A. Akhmedov, G. G. Camici, K. Shojaati, N. Bogdanov, J. Steffel, D. Ringli, T. F. Luscher, and F. C. Tanner Cardiac Glycosides Regulate Endothelial Tissue Factor Expression in Culture Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2769 - 2776. [Abstract] [Full Text] [PDF]

				M. Ghosh, H. Wang, Y. Ai, E. Romeo, J. P. Luyendyk, J. M. Peters, N. Mackman, S. K. Dey, and T. Hla COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR{delta} activation J. Exp. Med., September 3, 2007; 204(9): 2053 - 2061. [Abstract] [Full Text] [PDF]

				Y. Zhao, S. Zhou, and C.-K. Heng Impact of Serum Amyloid A on Tissue Factor and Tissue Factor Pathway Inhibitor Expression and Activity in Endothelial Cells Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1645 - 1650. [Abstract] [Full Text] [PDF]

				S. Lu and M. C. Archer Celecoxib Decreases Fatty Acid Synthase Expression via Down-Regulation of c-Jun N-Terminal Kinase-1 Experimental Biology and Medicine, May 1, 2007; 232(5): 643 - 653. [Abstract] [Full Text] [PDF]

				W. B. White Cardiovascular Effects of the Cyclooxygenase Inhibitors Hypertension, March 1, 2007; 49(3): 408 - 418. [Full Text] [PDF]

				T. F. Luscher, J. Steffel, F. R. Eberli, M. Joner, G. Nakazawa, F. C. Tanner, and R. Virmani Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications Circulation, February 27, 2007; 115(8): 1051 - 1058. [Abstract] [Full Text] [PDF]

				J. M. Gitlin, D. B. Trivedi, R. Langenbach, and C. D. Loftin Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice Cardiovasc Res, January 1, 2007; 73(1): 227 - 236. [Abstract] [Full Text] [PDF]

				G. G. Camici, J. Steffel, A. Akhmedov, N. Schafer, J. Baldinger, U. Schulz, K. Shojaati, C. M. Matter, Z. Yang, T. F. Luscher, et al. Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell Activation: A Potential Treatment Strategy for Drug-Eluting Stents Circulation, October 3, 2006; 114(14): 1512 - 1521. [Abstract] [Full Text] [PDF]

				S. Chaiamnuay, J. J. Allison, and J. R. Curtis Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851. [Abstract] [Full Text] [PDF]

				B. E. Stahli, G. G. Camici, J. Steffel, A. Akhmedov, K. Shojaati, M. Graber, T. F. Luscher, and F. C. Tanner Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation Circ. Res., July 21, 2006; 99(2): 149 - 155. [Abstract] [Full Text] [PDF]

				M. Hermann and F. Ruschitzka Novel anti-inflammatory drugs in hypertension Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864. [Full Text] [PDF]

				J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]

				J. Steffel, R. A. Latini, A. Akhmedov, D. Zimmermann, P. Zimmerling, T. F. Luscher, and F. C. Tanner Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression: Implications for Drug-Eluting Stent Design Circulation, September 27, 2005; 112(13): 2002 - 2011. [Abstract] [Full Text] [PDF]

				M. Hermann, H. Krum, and F. Ruschitzka To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk Circulation, August 16, 2005; 112(7): 941 - 945. [Full Text] [PDF]

				J. Steffel, A. Akhmedov, H. Greutert, T. F. Luscher, and F. C. Tanner Histamine Induces Tissue Factor Expression: Implications for Acute Coronary Syndromes Circulation, July 19, 2005; 112(3): 341 - 349. [Abstract] [Full Text] [PDF]